Telix Pharmaceuticals Limited reported $804M of revenue over the trailing twelve months, +56% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $804M (to FY2025). Net income: −$7.1M, trailing twelve months to FY2025. Free cash flow: −$43M, trailing twelve months to FY2025. Operating margin: 3.7%, trailing twelve months to FY2025.

TLXTelix Pharmaceuticals Limited

Healthcare

$11.22+12% 1Y

$11.22

$6.4152 weeks$12.84

TLX as reported

Telix Pharmaceuticals Limited reported $804M of revenue over the trailing twelve months, +56% on the year before. 10 reported series are charted on this page, each one as filed.

$804M

Revenue, trailing twelve months · to FY2025 · +56% against the twelve months before

Net income: −$7.1M
Net income · −121% year on year · trailing twelve months to FY2025
Free cash flow: −$43M
Free cash flow · −334% year on year · trailing twelve months to FY2025
Operating margin: 3.7%
Operating margin · trailing twelve months to FY2025

Details›

Every series Ryufin has for TLX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$804M	+56%	FY2025
Net income	−$7.1M	−121%	FY2025
EPS	−$0.02	−122%	FY2025
Gross margin	53%	n/a	FY2025
Operating margin	3.7%	n/a	FY2025
Net margin	−0.89%	n/a	FY2025
ROE	−1.7%	n/a	FY2025
ROA	−0.61%	n/a	FY2025
ROIC	3.5%	n/a	FY2025
Free cash flow	−$43M	−334%	FY2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.